Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

1.

The validity, reliability and acceptability of the SAVASI; a new self-assessment score in vitiligo.

Komen L, van der Kraaij GE, van der Veen JP, de Rie MA, Wolkerstorfer A.

J Eur Acad Dermatol Venereol. 2015 Apr 13. doi: 10.1111/jdv.13161. [Epub ahead of print]

PMID:
25868111
2.

Fractionated carbon dioxide laser therapy as treatment of mild rhinophyma: report of three cases.

Meesters AA, van der Linden MM, De Rie MA, Wolkerstorfer A.

Dermatol Ther. 2015 Mar 5. doi: 10.1111/dth.12205. [Epub ahead of print]

PMID:
25753618
3.

Vitiligo Area Scoring Index and Vitiligo European Task Force assessment: reliable and responsive instruments to measure the degree of depigmentation in vitiligo.

Komen L, da Graça V, Wolkerstorfer A, de Rie MA, Terwee CB, van der Veen JP.

Br J Dermatol. 2015 Feb;172(2):437-43. doi: 10.1111/bjd.13432. Epub 2015 Jan 8.

PMID:
25278165
4.

The IL-17A-producing CD8+ T-cell population in psoriatic lesional skin comprises mucosa-associated invariant T cells and conventional T cells.

Teunissen MB, Yeremenko NG, Baeten DL, Chielie S, Spuls PI, de Rie MA, Lantz O, Res PC.

J Invest Dermatol. 2014 Dec;134(12):2898-907. doi: 10.1038/jid.2014.261. Epub 2014 Jun 18.

PMID:
24945094
5.

A Web-based, educational, quality-of-life intervention for patients with a chronic skin disease: feasibility and acceptance in routine dermatological practice.

van Cranenburgh OD, Smets EM, de Rie MA, Sprangers MA, de Korte J.

Acta Derm Venereol. 2015 Jan;95(1):51-6. doi: 10.2340/00015555-1872.

6.

Drug survival is not significantly different between biologics in patients with psoriasis vulgaris: a single-centre database analysis.

Menting SP, Sitaram AS, Bonnerjee-van der Stok HM, de Rie MA, Hooft L, Spuls PI.

Br J Dermatol. 2014 Oct;171(4):875-83. doi: 10.1111/bjd.13001. Epub 2014 Aug 21.

PMID:
24673245
7.

Q-switched laser depigmentation in vitiligo, most effective in active disease.

Komen L, Zwertbroek L, Burger SJ, van der Veen JP, de Rie MA, Wolkerstorfer A.

Br J Dermatol. 2013 Dec;169(6):1246-51. doi: 10.1111/bjd.12571.

PMID:
23909405
8.

Port-wine stain progression: is prevention by pulsed dye laser therapy possible?

van Drooge AM, de Rie M, van der Veen W, Wolkerstorfer A.

Eur J Dermatol. 2013 Apr 1;23(2):282-3. doi: 10.1684/ejd.2013.1998. No abstract available.

PMID:
23608049
9.

Satisfaction with treatment among patients with psoriasis: a web-based survey study.

van Cranenburgh OD, de Korte J, Sprangers MA, de Rie MA, Smets EM.

Br J Dermatol. 2013 Aug;169(2):398-405. doi: 10.1111/bjd.12372.

PMID:
23565643
10.

A prospective, randomized, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on lesional and nonlesional skin.

de Groot M, Picavet DI, van Kuijk AW, Tak PP, Bos JD, de Rie MA, Teunissen MB.

Dermatology. 2012;225(4):298-303. doi: 10.1159/000343290. Epub 2012 Dec 21.

PMID:
23257348
11.
12.

Long-pulsed 1064 nm Nd:YAG laser improves hypertrophic port-wine stains.

van Drooge AM, Bosveld B, van der Veen JP, de Rie MA, Wolkerstorfer A.

J Eur Acad Dermatol Venereol. 2013 Nov;27(11):1381-6. doi: 10.1111/jdv.12021. Epub 2012 Oct 24.

PMID:
23094931
13.

Expression of IL-20 in synovium and lesional skin of patients with psoriatic arthritis: differential response to alefacept treatment.

Lebre MC, Jonckheere CL, Kraan MC, van Kuijk AW, Bos JD, de Rie M, Gerlag DM, Tak PP.

Arthritis Res Ther. 2012 Sep 24;14(5):R200. doi: 10.1186/ar4038.

14.

Rise in dermal CD11c+ dendritic cells associates with early-stage development of psoriatic lesions.

Teunissen MB, Zheng L, de Groot M, de Rie MA, Fine JS, Chen SC.

Arch Dermatol Res. 2012 Aug;304(6):443-9. doi: 10.1007/s00403-012-1231-7. Epub 2012 Mar 22.

15.

Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor.

Skvara H, Kalthoff F, Meingassner JG, Wolff-Winiski B, Aschauer H, Kelleher JF, Wu X, Pan S, Mickel L, Schuster C, Stary G, Jalili A, David OJ, Emotte C, Antunes AM, Rose K, Decker J, Carlson I, Gardner H, Stuetz A, Bertolino AP, Stingl G, De Rie MA.

J Invest Dermatol. 2011 Aug;131(8):1735-44. doi: 10.1038/jid.2011.48. Epub 2011 Mar 24.

16.

Etanercept: an overview of dermatologic adverse events.

Lecluse LL, Dowlatshahi EA, Limpens CE, de Rie MA, Bos JD, Spuls PI.

Arch Dermatol. 2011 Jan;147(1):79-94. doi: 10.1001/archdermatol.2010.410. Review.

PMID:
21242398
17.

Reduction of different inflammatory cell types of the innate immune system in psoriatic skin during etanercept treatment.

de Groot M, Teunissen MB, Picavet DI, de Rie MA, Bos JD.

Exp Dermatol. 2010 Aug;19(8):754-6. doi: 10.1111/j.1600-0625.2010.01089.x.

PMID:
20482616
18.

Alice, Eloi, Magali and Robert: the lives of four patients with psoriasis and the therapeutic approaches of eight European experts.

Dubertret L, Chimenti S, Christophers E, Daudén E, de Rie M, Griffiths CE, Kragballe K, Ståhle M, Stingl G.

Br J Dermatol. 2009 Aug;161 Suppl 2:1-30. doi: 10.1111/j.1365-2133.2009.09173.x. No abstract available.

PMID:
19594542
19.

Expression of chemokine receptor CXCR3 by lymphocytes and plasmacytoid dendritic cells in human psoriatic lesions.

Chen SC, de Groot M, Kinsley D, Laverty M, McClanahan T, Arreaza M, Gustafson EL, Teunissen MB, de Rie MA, Fine JS, Kraan M.

Arch Dermatol Res. 2010 Mar;302(2):113-23. doi: 10.1007/s00403-009-0966-2. Epub 2009 Jun 11.

PMID:
19517126
20.

Survey among patients with basal cell carcinoma in The Netherlands.

Gerritsen MJ, De Rie MA, Beljaards RC, Thissen MR, Kuipers MV.

J Dermatolog Treat. 2009;20(4):213-8. doi: 10.1080/09546630802647236.

PMID:
19125362
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk